Real-world evidence · Neurology evidence generation

Turning messy real-world data into evidence people can trust.

I'm Sonick. For eight years I've designed and delivered studies from Claims and EHR data, from patient journeys and treatment patterns to biomarker research, for global pharmaceutical clients.

8 years
in real-world evidence
5
publications & conference abstracts
10+
RWE studies delivered
6
person team led

  1. 01 · SOURCE

    Claims and EHR

  2. 02 · CURATE

    Abstraction, QC, fit-for-purpose data

  3. 03 · ANALYSE

    Cohorts, endpoints, statistics

  4. 04 · EVIDENCE

    Publications & client decisions

What I do

Evidence generation from real-world data, from the first feasibility question to publication.

RWE study design & analysis

Retrospective studies with Kaplan-Meier and Cox models, interrupted time series, regression and concordance analysis.

Treatment patterns & persistence

Switching, persistence and discontinuation, healthcare resource use and real-world endpoints such as relapse and infections.

AI-enabled chart abstraction

LLM pipelines that turn clinical notes and lab reports into analysis-ready variables, validated for PPV, sensitivity and F1.

RWD for trial feasibility

Turning eligibility criteria into cohort definitions and attrition funnels to find and match patients for studies.

Selected work

ALZHEIMER'S · BIOMARKERS · CTAD

Diagnostic pathways to anti-amyloid therapy

Compared blood-based biomarkers, PET and CSF in routine care, found care gaps and the fastest route to anti-amyloid therapy, and mapped the patient journey from cognitive assessment to biomarker results.

ALZHEIMER'S · PERSISTENCE

Anti-amyloid therapy persistence

Kaplan-Meier analysis of real-world time to discontinuation, stratified by biomarker status, to find what drives patients to stop treatment.

MULTIPLE SCLEROSIS · TREATMENT PATTERNS

Disease-modifying therapy in real-world MS care

Led a retrospective study comparing DMT classes on switching, healthcare resource use and relapse, with real-world endpoints extracted from clinical notes by a validated LLM pipeline.

RESPIRATORY · ISPOR EUROPE 2023

COVID-19's impact on RSV and influenza

Interrupted time series models quantifying how RSV and influenza incidence changed before and after COVID-19 in the US and EU-5.

PYTHON · SYNTHETIC EHR · PERSONAL PROJECT

What real-world data can and can't tell you about trial eligibility

5,000 synthetic patients vs. a Phase 3 Alzheimer's protocol: 14.6% pass the checks an EHR can make; 5.5% are fully eligible.

COMMERCIAL ANALYTICS · CLAIMS

Launch planning & prescriber targeting

Treatment-pattern dashboards for an oncology portfolio, forecast inputs from claims, and HCP segmentation from prescription and distribution data.

Publications & conference abstracts

  1. CTAD · upcomingUS real-world patterns of amyloid testing and anti-amyloid therapy initiation in Alzheimer's disease and mild cognitive impairment
  2. medRxiv · 2025NeuroDiscovery AI Database: a comprehensive EHR dataset for neurology
  3. ISPOR Europe · 2023Exploring RSV and influenza trends pre- and post-COVID-19 in the US and EU-5 countries
  4. EULAR · 2020Patient characteristics, comorbidities and infection outcomes among RA patients in Puerto Rico
  5. Journal articleTreatment patterns among patients with rheumatoid arthritis in Puerto Rico

Data & tools

  • Medical & pharmacy claims
  • EHR
  • Clinical notes & lab reports
  • HCP surveys
  • MarketScan
  • Flatiron
  • IQVIA
  • SAS
  • R
  • Python
  • SQL
  • Databricks
  • Instant Health Data
  • LLM extraction

Experience

Eight years across a health-tech start-up, a CRO, a global pharma company and analytics consulting.

Education

PG Diploma in Applied Statistics, IGNOU (2020–2022)
B.Tech, Electrical & Electronics Engineering, Amity University (2014–2018)

Recognition

Lilly Star Award, Eli Lilly
SPOT Award, Mu Sigma

  1. May 2026 – PresentAssociate Director, Clinical Trial Enrolment & Implementation Sciences
    NeuroDiscovery AI · Led a six-person team matching patients to Alzheimer's and epilepsy studies from real-world data, and AI-enabled chart abstraction.
  2. Sep 2024 – May 2026Senior RWE Analyst
    NeuroDiscovery AI · Foundation hire who helped build the RWE function; Alzheimer's and MS studies.
  3. Jul 2023 – Sep 2024Data Scientist II
    Syneos Health · Time series, forecasting and prescriber analytics from claims and IQVIA data.
  4. Apr 2022 – Jul 2023Associate Manager
    Eli Lilly · Oncology treatment-pattern analyses with MarketScan claims and Flatiron EHR.
  5. Dec 2018 – Mar 2022Trainee Decision Scientist → Apprentice Leader
    Mu Sigma · 10+ RWE studies in cardiovascular and immunology from claims and EHR data.

Writing

Notes on real-world evidence. First posts coming soon.

Visit the blog

Have a real-world evidence question?

Open to RWE leadership roles and select consulting projects. Based in Gurugram, India, working with teams in the US and Europe.

contact@sonicksuri.com LinkedIn